<DOC>
	<DOCNO>NCT00502060</DOCNO>
	<brief_summary>Phase I AZD2171 combination ZD1839 study recruit patient advance cancer</brief_summary>
	<brief_title>Phase I Study AZD2171 co-Administered With Fixed Multiple Oral Doses ZD1839 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>tumor progress standard therapy ineligible standard therapy life expectancy 12 week WHO performance status 02 History active interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AZD2171</keyword>
	<keyword>ZD1839</keyword>
	<keyword>solid tumor</keyword>
</DOC>